Loading...
XNAS
CVRX
Market cap44mUSD
Oct 08, Last price  
1.68USD
1D
0.60%
1Q
-69.06%
IPO
-93.56%
Name

CVRx Inc

Chart & performance

D1W1MN
XNAS:CVRX chart
P/E
—
P/S
0.79
EPS
—
Div yield, %
—
Shrs. gr., 5y
132.12%
Rev. gr., 5y
56.40%
Revenues
57m
+10.45%
6,257,0006,053,00013,036,00022,469,00039,295,00051,292,00056,651,000
Net income
-53m
L-11.10%
-14,633,000-14,109,000-43,078,000-41,428,000-41,199,000-59,965,000-53,306,000
CFO
-40m
L+2.62%
-12,785,000-16,096,000-27,732,000-42,677,000-39,021,000-39,144,000-40,170,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Key people

Nadim Yared
President, Chief Executive Officer, Director
Robert S. Kieval
Founder, Director, Chief Development Officer · since 2016
Dean Bruhn-Ding
Vice President of Regulatory Affairs and Quality Assurance
Ali Behbahni
Director
Michael P. Chuisano
Director
A. Jay Graf
Director
Josep Lluis Sanfeliu
Director
Joseph P. Slattery
Director
John R. Brintnall
Chief Financial Officer
URL
https://www.cvrx.com/
IPO date
Jun 30, 2021
Employees
160
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT